<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728492</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-13-NSCLC/OVA-7-QUI-1B</org_study_id>
    <nct_id>NCT02728492</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy</brief_title>
  <official_title>Open-label Multicenter Multiple Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Gemcitabine + Cisplatin Chemotherapy (Second Line for Patients With Non-small Cell Lung Cancer) or Paclitaxel + Carboplatin Chemotherapy (Second Line for Patients With Non-small-cell Lung Cancer, Second and Subsequent Lines for Patients With Epithelial Ovarian Cancer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewVac LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceutica N.V., Belgium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NewVac LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quisinostat besides its own efficacy, which can potentially lead to better results of&#xD;
      polychemotherapy and increase the mean time to progression, it may be demonstrated that&#xD;
      Quisinostat leads to sustained tumor sensitivity to platinum drugs. In this study safety and&#xD;
      tolerability of multiple administrations of Quisinostat in doses ranging from 8 mg to 12 mg&#xD;
      combined with standard backbone chemotherapy in patients with non-small cell lung cancer&#xD;
      (second line) and ovarian cancer (second and subsequent lines) will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was proven that Quisinostat increases HDAC1-inhibited E-cadherin expression (at the low&#xD;
      concentrations of 30 nM) which increases susceptibility to epidermal growth factor inhibitors&#xD;
      in case of non-small-cell lung cancer and stops proliferation of paclitaxel-resistant cells.&#xD;
      Thus, besides its own efficacy, which can potentially lead to better results of&#xD;
      polychemotherapy and increase the mean time to progression, it may be demonstrated that&#xD;
      Quisinostat leads to sustained tumor sensitivity to platinum drugs and possibly to&#xD;
      resensitiztion in case of acquired or primary resistance.&#xD;
&#xD;
      The main objective of the study is to evaluate the safety and tolerability of Quisinostat in&#xD;
      multiple ascending doses and establish its maximum tolerated dose (MTD), administered in&#xD;
      combination with standard backbone chemotherapy, as follows: Gemcitabine + Cisplatin in&#xD;
      patients with non-small-cell lung cancer (second line) and Paclitaxel + Carboplatin in&#xD;
      patients with non-small-cell lung cancer (second line) and in patients with ovarian cancer&#xD;
      (second and subsequent lines). MTD is defined as maximum dose at which DLT occurs in no more&#xD;
      than 1 patient of 6.&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
      • Study of pharmacokinetics (PK) of multiple dosing of Quisinostat administered in&#xD;
      combination with chemotherapy, as follows: Gemcitabine + Cisplatin in patients with&#xD;
      non-small-cell lung cancer (second line) and Paclitaxel + Carboplatin in patients with&#xD;
      non-small-cell lung cancer (second line) and in patients with ovarian cancer (second and&#xD;
      subsequent lines) Preliminary estimation of possible effect of the drug, added to&#xD;
      chemotherapy, on tumor growth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of Quisinostat based on number of patients with treatment -related AEs assessed by CTCAE v4.0, number of patients with abnormal laboratory values and instrumental tests (ECG) that are related to treatment</measure>
    <time_frame>22 weeks</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Quisinostat</measure>
    <time_frame>Day 1, Day 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the Quisinostat plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 1, Day 7</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Quisinostat 8 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 8 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 10 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 10 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 12 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 12 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 8 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 8 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 10 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 10 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 12 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1250 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quisinostat 12 mg capsule every other day and Gemcitabine 1250 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quisinostat</intervention_name>
    <arm_group_label>Quisinostat 10 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 10 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1250 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 8 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 8 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <other_name>JNJ-26481585</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Quisinostat 10 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 8 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Quisinostat 10 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
    <arm_group_label>Quisinostat 8 mg &amp; Paclitaxel &amp; Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Quisinostat 10 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1250 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 8 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Quisinostat 10 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 12 mg &amp; Gemcitabine 1250 mg/m2 &amp; Cisplatin</arm_group_label>
    <arm_group_label>Quisinostat 8 mg &amp; Gemcitabine 1000 mg/m2 &amp; Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General criteria for the inclusion of patients with non-small cell lung cancer (NSCLC) and&#xD;
        ovarian cancer (OC):&#xD;
&#xD;
          1. Signed patient's information sheet and informed consent form to participate in the&#xD;
             study&#xD;
&#xD;
          2. Age 18 and older&#xD;
&#xD;
          3. The value of left ventricular ejection fraction, as determined by echocardiography&#xD;
             data, more than 50%&#xD;
&#xD;
          4. Patient's ability to carry out visits and study procedures and to comply with the&#xD;
             protocol&#xD;
&#xD;
          5. Requirements to laboratory parameters determined below:&#xD;
&#xD;
             Complete blood count: Absolute neutrophil count:&#xD;
&#xD;
             Platelets:&#xD;
&#xD;
             Haemoglobin: ≥ 1500/mm3 (1.5 x 109 cells/l)&#xD;
&#xD;
               -  100 000/mm3 (100 x 109 cells/l)&#xD;
&#xD;
               -  9.0 g/dl&#xD;
&#xD;
             Liver function: Total bilirubin:&#xD;
&#xD;
             aspartate aminotransferase (AST) and alanine aminotransferase (ALT): ≤ 1.5-fold of the&#xD;
             upper limit of normal (ULN)&#xD;
&#xD;
             ≤ 2.5--fold of ULN or ≤ 5.0-fold of ULN in case of metastases in liver Kidney&#xD;
             function: GRF (by Cockcroft-Gault equation) &gt; 50 ml/min&#xD;
&#xD;
          6. The expected survival time not less than 6 months&#xD;
&#xD;
          7. Women and men of childbearing potential (not sterile or in menopause less than 2&#xD;
             years) must be practicing an effective method of birth control starting from the&#xD;
             screening period, during the study and 6 months after the last administration of the&#xD;
             investigational product. Effective methods include use a condom or diaphragm (barrier&#xD;
             method) with spermicide.&#xD;
&#xD;
          8. Functional status of the patient according to the ECOG 0 - 2 Special criteria for&#xD;
             patients with NSCLC&#xD;
&#xD;
          9. Histologically or cytologically confirmed diagnosis of non-resectable non-small-cell&#xD;
             lung cancer&#xD;
&#xD;
         10. The progression of lung cancer after a maximum of one line of systemic anticancer&#xD;
             therapy (adjuvant chemotherapy will be considered first-line therapy if the time from&#xD;
             the moment of its completion until disease progression was less than 6 months)&#xD;
&#xD;
         11. No history of treatment with Gemcitabine if the patient is planned for inclusion in&#xD;
             the group of chemotherapy with Cisplatin and Gemcitabine, or Paclitaxel if the patient&#xD;
             is planned for inclusion in the group of Carboplatin and Paclitaxel.&#xD;
&#xD;
         12. Vital capacity of lung by spirometry data is more than 50% of normal at screening&#xD;
&#xD;
             Special inclusion criteria for patients with ovarian cancer&#xD;
&#xD;
         13. Histologically confirmed diagnosis of ovarian cancer.&#xD;
&#xD;
         14. Progression after no more than three modes of anticancer drug therapy for ovarian&#xD;
             cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Indications for X-ray therapy or chemoradiation therapy at the time of inclusion,&#xD;
             regardless of the treated area;&#xD;
&#xD;
          2. Presence of clinical and/or radiological signs of metastases in the brain and&#xD;
             meningeal structures (CNS);&#xD;
&#xD;
          3. Previous therapy with HDAC inhibitors&#xD;
&#xD;
          4. Any contraindications to the chemotherapy with Gemcitabine + Cisplatin or Paclitaxel +&#xD;
             Carboplatin (in patients with lung cancer); contraindications to chemotherapy&#xD;
             according to the standard chemotherapy combination scheme Paclitaxel + Carboplatin (in&#xD;
             female patients with ovarian cancer);&#xD;
&#xD;
          5. Any contraindications to administration of glucocorticosteroids, antihistamine drugs,&#xD;
             serotonin 5-HT3 receptor antagonists, aprepitant;&#xD;
&#xD;
          6. Any contraindications to forced rehydration and/or administration of forced diuresis&#xD;
             (in case of lung cancer);&#xD;
&#xD;
          7. Conditions that require continuous use of oral anticoagulants, or clinically&#xD;
             significant changes in blood coagulation parameters at screening (INR &gt; 1.5, aPTT&gt; 1.5&#xD;
             х ULN)&#xD;
&#xD;
          8. Conditions that require admission of prohibited drugs, or impossibility to replace&#xD;
             those with allowed drugs in the study&#xD;
&#xD;
          9. Current infection or other systemic conditions constituting a contraindication to the&#xD;
             intended chemotherapy;&#xD;
&#xD;
         10. Diseases of the digestive system which may infringe absorption of the investigational&#xD;
             product (Crohn's disease, nonspecific ulcerative colitis, irritable bowel syndrome)&#xD;
&#xD;
         11. Clinically significant cardiovascular diseases including:&#xD;
&#xD;
               -  Myocardial infarction within 12 months before screening&#xD;
&#xD;
               -  Unstable angina within 12 months before screening&#xD;
&#xD;
               -  Congestive heart failure Class III or IV according to the New York Heart&#xD;
                  Association criteria (NYHA)&#xD;
&#xD;
               -  Clinically significant ventricular arrhythmia including ventricular tachycardia,&#xD;
                  ventricular fibrillation, history of cardiac arrest, atrioventricular block&#xD;
                  (Mobitz II or III), use of cardiostimulator&#xD;
&#xD;
               -  QTc interval &gt; 450 ms in men or 470 ms in women (ECG) (calculated according to&#xD;
                  Fredericia formula), or a diagnosis of long QT syndrome&#xD;
&#xD;
               -  Hypotension (systolic blood pressure &lt; 86 mm Hg or bradycardia with a heart rate&#xD;
                  of &lt; 50 beats per minute (ECG) except when caused by medications (e.g.&#xD;
                  beta-blockers).&#xD;
&#xD;
               -  Uncontrolled arterial hypertension (systolic arterial pressure &gt; 170 millimeters&#xD;
                  of mercury or diastolic blood pressure &gt; 105 millimeters of mercury)&#xD;
&#xD;
         12. Pregnancy and lactation&#xD;
&#xD;
         13. Presence of HIV antibodies, Hepatitis В and С antibodies&#xD;
&#xD;
         14. Drug or alcohol abuse at the moment of screening or in the past which according to the&#xD;
             opinion of the Investigator makes the patient unsuitable for participation in the&#xD;
             study&#xD;
&#xD;
         15. Significant allergic reactions in medical history&#xD;
&#xD;
         16. Participation in other clinical studies or administration of test drugs during 30 days&#xD;
             before beginning of the study or persisting side effect of any of the test drugs;&#xD;
&#xD;
         17. Toxic effects of previous treatments or complications after surgical treatments that&#xD;
             did not resolve to grades 1 and/or 0 (according to the CTCAE scale).&#xD;
&#xD;
         18. Patient not willing to participate in the study or unable to understand or follow the&#xD;
             protocol instructions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Tjulandin, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Russian Oncological Research Center n.a. N. N. Blokhin RAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Russian Oncological Research Center n.a. N. N. Blokhin RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Stavropol Territory &quot;Pyatigorsk oncology dispensary&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Peterburg State Budgetary healthcare Institution &quot;City Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioEq LLC</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution of healthcare &quot;Saint-Petersburg clinical research and practical centre of specialized medical aid (oncology)&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Yaroslavl region &quot;Regional Clinical oncology hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Final results will be published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

